G-protein Coupled Receptors (GPCRs): A Potential Target of Apigenin as a Novel hACE2 Receptor Specific Therapeutic for Impeding Lung Cancer Considering a Group of Missense and Nonsense Mutations in COVID-19 Patients

Rasel Ahmed, Sharmin Akter, Fnu Nurunnahar, Sabiha Sultana, Sabbir Hasan, Sharmin Ahmed, Md. Al Hasibuzzaman, Syed Nafis Shadman Ali, Ramisha Tahsin, Nasiha Tahsin, Niloy Das and Mohammad Habibur Rahman
Additional contact information
Rasel Ahmed: Teesside University, United Kingdom
Sharmin Akter: Indiana State University, USA
Fnu Nurunnahar: Mawlana Bhashani Science and Technology University, Bangladesh
Sabiha Sultana: Illinois State University, USA
Sabbir Hasan: Otto Von Guericke University, Germany
Sharmin Ahmed: Jashore Medical College, Bangladesh
Md. Al Hasibuzzaman: Ningbo University, PR China
Syed Nafis Shadman Ali: North South University, Bangladesh
Ramisha Tahsin: North South University, Bangladesh
Nasiha Tahsin: North South University, Bangladesh
Niloy Das: University Bangladesh, Bangladesh
Mohammad Habibur Rahman: Bangladesh Agricultural University, Bangladesh

European Journal of Pharmaceutical Research, 2025, vol. 5, issue 1, 6-15

Abstract: This research investigates the role of mutation cascades in enhancing COVID-19-related lung cancer fatalities, specifically through analyzing mutations in the ACE2 gene associated with SARS-CoV-2 infections. Notably, a natural flavonoid, apigenin, has been identified as a promising hACE2-specific therapeutic. The study involved detailed examinations of 27 mutations (23 missense and four nonsense) and the molecular interactions between apigenin and hACE2, revealing a binding energy of -8.1 Kcal/mol. Various molecular dynamics parameters suggested stable interactions, while the drug-gene interaction analysis demonstrated that 18 GPCR genes could metabolize apigenin, effectively blocking hACE2 and thereby inhibiting S-protein attachment. The findings propose that apigenin could serve as a targeted therapy for COVID-19-induced lung cancer.

Keywords: Apigenin-hACE2 complexing; COVID 19 associated lung cancer; G-protein coupled receptor (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://eu-opensci.org/index.php/pharma/article/view/785 Abstract page (text/html)
https://eu-opensci.org/index.php/pharma/article/download/785/325 Full text (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:epw:pharma:v:5:y:2025:i:1:id:785

DOI: 10.24018/ejpharma.2025.5.1.85

Access Statistics for this article

More articles in European Journal of Pharmaceutical Research from European Open Science Publishing
Bibliographic data for series maintained by Support Team ().